IPC partners with fellow nonprofits in dermatology and psoriasis to share knowledge, collaborate on research, and advocate for better patient care worldwide.
The International Federation of Psoriasis Associations (IFPA) is a nonprofit organization that unites national and regional psoriasis associations worldwide. Since their founding in 1971, they have worked to address the international psoriasis community’s challenges. IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis, with goals to empower members, improve patients’ living conditions, raise awareness, and collaborate with fellow stakeholders.
The IPC and IFPA are currently working together on:
– Global Psoriasis Atlas (GPA)
– Recategorization of disease severity
– Telemedicine
– Diverse Skin Tones
The National Psoriasis Foundation (NPF) is a nonprofit organization in the United States dedicated to finding a cure for psoriasis and psoriatic arthritis. It serves as a resource for individuals affected by these conditions, providing support, education, and advocacy. The NPF conducts research, raises awareness, and works to improve access to effective treatments and healthcare for people living with psoriasis and psoriatic arthritis.
Founded in 2003, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) is an international nonprofit consortium dedicated to advancing research, education, and patient care in psoriasis and psoriatic arthritis. GRAPPA brings together more than 1,000 rheumatologists, dermatologists, radiologists, epidemiologists, geneticists, patient research partners, and other experts from around the world. Through treatment recommendations, outcome measures, educational programs, and collaborative research initiatives, GRAPPA works to improve the understanding, diagnosis, and management of psoriatic disease globally. Approximately 75% of its members are based outside North America, reflecting its international reach.
The International Eczema Council (IEC) is a global nonprofit organization led by dermatology and allergy experts in atopic dermatitis, founded in 2014 and dedicated to improving patient care by promoting research, education, and best practices in the management of atopic dermatitis worldwide.
The IEC is governed by a Board of Directors comprised primarily of leading international experts in atopic dermatitis, including a patient representative. Today, more than 180 Councilors and Associates from over 35 countries across six regions contribute their expertise to support the IEC’s research, educational programs, and global initiatives.
Founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health worldwide for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology (WCD). Today, the ILDS represents dermatology at the highest level, with over 180 Member Societies from more than 80 countries, representing over 200,000 dermatologists. ILDS works closely with partners worldwide, including the World Health Organization (WHO), with whom it maintains official relations, to improve skin health for all people.
The Pan-American League of Associations for Rheumatology (PANLAR), founded in 1944, brings together national rheumatology societies, healthcare professionals, and patient groups from across North, Central, and South America. Its mission is to improve the lives of people living with rheumatic diseases throughout the Americas by advancing research, education, and clinical care, while promoting early diagnosis, access to treatment, and equitable standards of care across the region. PANLAR supports scientific exchange, guideline development, educational initiatives, and international congresses that advance the understanding and management of rheumatic diseases.
Founded in Buenos Aires, Argentina, in July 2008, SOLAPSO was established by dermatologists committed to advancing the understanding, diagnosis, and treatment of psoriasis in Latin America. Formally established as a civil association in November 2008, SOLAPSO promotes regional awareness through events across multiple countries and supports scientific publications focused on psoriasis in Latin America.
A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.
Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.
IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.
In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.
